Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "anthracyclines" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-6 z 6
    Tytuł:
    A simple model for predicting the free energy of binding between anthracycline antibiotics and DNA.
    Autorzy:
    Rudnicki, Witold
    Kurzepa, Małgorzata
    Szczepanik, Teresa
    Priebe, Waldemar
    Lesyng, Bogdan
    Powiązania:
    https://bibliotekanauki.pl/articles/1044384.pdf
    Data publikacji:
    2000
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    anthracyclines
    free energy
    modelling
    DNA
    Opis:
    A theoretical model for predicting the free energy of binding between anthracycline antibiotics and DNA was developed using the electron density functional (DFT) and molecular mechanics (MM) methods. Partial DFT-ESP charges were used in calculating the MM binding energies for complexes formed between anthracycline antibiotics and oligodeoxynucleotides. These energies were then compared with experimental binding free energies. The good correlation between the experimental and theoretical energies allowed us to propose a model for predicting the binding free energy for derivatives of anthracycline antibiotics and for quickly screening new anthracycline derivatives.
    Źródło:
    Acta Biochimica Polonica; 2000, 47, 1; 1-9
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Delayed anthracycline-induced cardiomyopathy – case report
    Autorzy:
    Wiater, Elżbieta
    Charliński, Grzegorz
    Magoń-Golińska, Małgorzata
    Powiązania:
    https://bibliotekanauki.pl/articles/773506.pdf
    Data publikacji:
    2014
    Wydawca:
    Medical Education
    Tematy:
    anthracyclines
    cardiomyopathy
    case report
    Opis:
    A 43-year-old man was admitted to the hematology department due to second recurrence of anaplastic lymphoma T-cell ALK+. Lymphoma was diagnosed 28 years earlier. The patient received COP regimen (17 cycles) and CHOP (5 cycles), radiotherapy and underwent splenectomy. He achieved complete remission at that time. Relapse of the disease was diagnosed 8 years later, which was treated with 6 cycles of chemotherapy (cytarabine, mitoxantrone, vepeside and glucocorticoids) and high-dose chemotherapy followed by hematopoietic stem cell transplantation. Second disease recurrence was found in 2013, it was anaplastic lymphoma T-cell ALK+ stage IIA by Ann Arbor. Echocardiography and myocardial perfusion scintigraphy revealed chronic heart failure NYHA class I. Angiotensin receptor antagonist (ramipril) and β-blocker (carvedilol) were recommended. The patient underwent 6 cycles of ESHAP, complete remission was reported after the second cycle. High-dose therapy with autologous stem cell rescue was considered at that time. However, having T-cell ALK+ lymphoma with a relatively good prognosis, previous prolonged complete remissions (respectively – 12 and 8 years), an insufficient yield from the harvest (3,33 × 106/kg CD34+ cells), heart failure and chronic active viral hepatitis B, the high risk intensive chemotherapy followed by hematopoietic stem cells transplantation was discontinued. The chemotherapy was complicated by brachial vein and superficial vein thrombosis of left upper limb and hypogammaglobulinemia. Follow-up echocardiography performed after completion of chemotherapy showed improvement in EF (64%).
    Źródło:
    OncoReview; 2014, 4, 4; A155-A159
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Outcome of anthracycline-related cardiomyopathy – experience of a cardiooncology clinic at a tertiary referral cancer centre
    Autorzy:
    Alahari Dhir, Aruna
    Daddi, Anuprita
    Sawant, Sheela Prashant
    Powiązania:
    https://bibliotekanauki.pl/articles/1061992.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    anthracyclines
    chemotherapy
    left ventricular dysfunction
    Opis:
    Introduction: The most common form of cardiotoxicity in cancer treatment is anthracycline-related cardiomyopathy. Objective: To study the factors affecting response to heart failure (HF) therapy in patients with anthracycline- related cardiomyopathy (ARC). Methods: Patients with ARC were included in the study. ARC was defined as left ventricular ejection fraction (LVEF) < 50% in patients who had received anthracycline based chemotherapy. 2Decho was done at baseline and every 3 months after starting anti-heart failure treatment. The primary endpoint of the study was response to anti-heart failure treatment. The patients were considered as responders when LVEF increased at least 10 absolute points. The secondary endpoint was overall survival. Results: 177 patients with ARC were included in the study. The median cumulative dose of doxorubicin was 275 mg/m2. Median clinical follow up duration was 19 months (range 3–73 months). 55% were responders. 25 cumulative doxorubicin dose of more than 200 mg/m2 increased the likelihood of non-response (p = 0.008), by a factor of 3.07 (95% CI: 1.34–7.05). 25 patients expired. There was a significant difference in overall survival among responders as compared to non-responders (p value: 0.002, log rank test). Conclusions: In patients with ARC cumulative doxorubicin dose of more than 200 mg/m2 increased the likelihood of non-response to anti-heart failure treatment. Responders have a better overall survival compared to non-responders in patients with ARC.
    Źródło:
    OncoReview; 2017, 7, 4; 155-161
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Administration of liposomal doxorubicin in patients with metastatic breast cancer and significant concomitant cardiovascular conditions
    Autorzy:
    Bryjak, Agnieszka
    Powiązania:
    https://bibliotekanauki.pl/articles/773565.pdf
    Data publikacji:
    2014
    Wydawca:
    Medical Education
    Tematy:
    NLPD
    cardiotoxicity
    conventional anthracyclines
    liposomal doxorubicin
    metastatic breast cancer
    Opis:
    A frequent dilemma faced by an oncologist about to take decision on a chemotherapeutic regime for patients with metastatic breast cancer is how to maintain balance between the expected treatment efficacy and predictable adverse events. In the case of anthracyclines what is problematic is their significant cardiotoxicity, in particular with reference to patients previously treated with them as part of adjuvant therapy. A relatively new method is replacement of conventional doxorubicin with its non-pegylated form, encapsulated in liposomes, which is capable of minimizing the side effects without compromising its therapeutic index. The present article discusses three cases of patients treated with non-pegylated liposomal doxorubicin (NPLD) as first-line chemotherapy administered for metastatic breast cancer. In all three cases considerable clinical improvement was observed, involving remission of pathological lesions and good quality of life.
    Źródło:
    OncoReview; 2014, 4, 4; A148-A154
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Severe aortic stenosis in a patient with breast cancer
    Autorzy:
    Mańczak, Rafał
    Wilk, Michał
    Walaszkowska-Czyż, Anna
    Florczyk, Michał
    Szmit, Sebastian
    Powiązania:
    https://bibliotekanauki.pl/articles/1064894.pdf
    Data publikacji:
    2016
    Wydawca:
    Medical Education
    Tematy:
    anthracyclines
    aortic stenosis
    aortic valve replacement
    breast cancer
    echocardiography
    Opis:
    We present a case of 68-year-old female with severe symptomatic aortic stenosis and locally advanced breast cancer disqualified from mastectomy due to heart failure and from aortic valve replacement due to malignant neoplasm. The patient received neoadjuvant chemotherapy without anthracyclines. The aortic valve replacement was performed and then mastectomy and lymphadenectomy were made without hemodynamic complications. Adjuvant hormonotherapy was started. During 42 months of follow-up the patient remained free of recurrent cancer disease as well as no progression of heart failure was observed.
    Źródło:
    OncoReview; 2016, 6, 2; A49-56
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
    Autorzy:
    Styczyński, Jan
    Wysocki, Mariusz
    Dębski, Robert
    Kurylak, Andrzej
    Balwierz, Walentyna
    Rokicka-Milewska, Roma
    Matysiak, Michał
    Balcerska, Anna
    Kowalczyk, Jerzy
    Wachowiak, Jacek
    Sońta-Jakimczyk, Danuta
    Chybicka, Alicja
    Powiązania:
    https://bibliotekanauki.pl/articles/1043814.pdf
    Data publikacji:
    2002
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    P-glycoprotein
    acute myeloblastic leukemia
    anthracyclines
    acute lymphoblastic leukemia
    drug resistance
    Opis:
    Uptake and efflux of two anthracyclines, idarubicin (IDA) and daunorubicin (DNR), was studied in childhood acute leukemia samples. A comparison of IDA and DNR transport phenomena in relation to drug cytotoxicity and expression of P-glycoprotein (PGP) was made. Intracellular content of IDA/DNR was determined by flow cytometry using the fluorescent properties of the drugs. In vitro drug cytotoxicity was measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. PGP expression was analysed by flow cytometry. The uptake and efflux rates were non-significantly higher for IDA than DNR. There were no differences between three types of leukemia with respect to drug content during accumulation and retention. After correction for the cell volume, intracellular concentration of both drugs in each moment of uptake and efflux was significantly lower in relapsed ALL and AML samples in comparison with initial ALL cells. Efflux, but not uptake, of both drugs was inversely correlated with PGP expression and IDA, but not DNR, cytotoxicity. The cytotoxicity was correlated with drug accumulation for both drugs and with drug retention for IDA. In conclusion, it seems that (1) intracellular content was related to the lipophilic properties of the drugs rather than to the type of leukemia, (2) decreased intracellular concentration of both drugs might have an impact on compromised therapy results in AML and relapsed ALL children, (3) IDA presents higher cytotoxicity, which possibly might be decreased by the presence of PGP. These results might have a practical impact on the rational design of new chemotherapy protocols.
    Źródło:
    Acta Biochimica Polonica; 2002, 49, 1; 99-107
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-6 z 6

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies